Neuroprotection of The Optic Nerve and The Retina

  • Kewal K. Jain
Part of the Springer Protocols Handbooks book series (SPH)


The optic nerve and the retina are extensions of the CNS. A variety of disease processes such as toxic, inflammatory, ischemic and degenerative affect the optic nerve and can lead to blindness. Neuroprotective approaches have been explored to prevent damage to the optic nerve from acquired causes rather than genetic disorders with impairment of vision due to abnormalities such as optic nerve hypoplasia.


  1. Amadio M, Pascale A, Cupri S, et al. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacol Res 2016;111:713–720.CrossRefGoogle Scholar
  2. Binley K, Widdowson PS, Kelleher M, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat®, for age-related macular degeneration. Hum Gene Ther 2012;23:980–91.CrossRefGoogle Scholar
  3. Butler F, Murphy-Lavoie H, Jain KK. In Jain KK: Textbook of Hyperbaric Medicine. 6th edition, Springer, New York, 2017.Google Scholar
  4. CATT Research Group. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 2011; 364:1897–1908.CrossRefGoogle Scholar
  5. Collier RJ, Patel Y, Martin EA, et al. Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci 2011;52:2118–26.CrossRefGoogle Scholar
  6. da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotech 2018;36:328–337.CrossRefGoogle Scholar
  7. Doonan F, Cotter TG. Norgestrel may be a potential therapy for retinal degenerations. Expert Opin Investig Drugs 2012;21:579–81.CrossRefGoogle Scholar
  8. Doonan F, O’Driscoll C, Kenna P, Cotter TG. Enhancing survival of photoreceptor cells in vivo using the synthetic progestin Norgestrel. J Neurochem 2011;118:915–27.CrossRefGoogle Scholar
  9. Ehrenberg M, Benny O. Evolving multidimensional pharmacological approaches to CNV therapy in AMD. Curr Eye Res 2018;43:147–154.CrossRefGoogle Scholar
  10. Fonseca-Kelly Z, Nassrallah M, Uribe J, et al. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 2012;3:84.CrossRefGoogle Scholar
  11. Guo X, Namekata K, Kimura A, et al. Brimonidine suppresses loss of retinal neurons and visual function in a murine model of optic neuritis. Neurosci Lett 2015;592:27–31.CrossRefGoogle Scholar
  12. Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010;133:2592–602.CrossRefGoogle Scholar
  13. Hoffmann DB, Williams SK, Bojcevski J, et al. Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. J Neuropathol Exp Neurol 2013;72:745–57.CrossRefGoogle Scholar
  14. Jaffe GJ, Schmitz-Valckenberg S, Boyer D, et al. Randomized Trial to Evaluate Tandospirone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study. Am J Ophthalmol 2015;160:1226–34.CrossRefGoogle Scholar
  15. Kashani AH, Lebkowski JS, Rahhal FM, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Science Translational Medicine 2019;10(435): eaao4097.CrossRefGoogle Scholar
  16. Klein R, Chou CF, Klein BE, et al. Prevalence of Age-Related Macular Degeneration in the US Population. Arch Ophthalmol 2011;129:75–80.CrossRefGoogle Scholar
  17. Klein R, Myers CE, Klein BE. Vasodilators, blood pressure-lowering medications, and age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2014 121:1604–11.CrossRefGoogle Scholar
  18. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591–7.CrossRefGoogle Scholar
  19. Lambiase A, Aloe L, Centofantic M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. PNAS 2009;106:13469–74.CrossRefGoogle Scholar
  20. Lee D, Kim KY, Noh YH, et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury. PLoS One 2012;7(10):e47098.CrossRefGoogle Scholar
  21. Lidster K, Jackson SJ, Ahmed Z, et al. Neuroprotection in a novel mouse model of multiple sclerosis. PLoS One 2013;8:e79188.CrossRefGoogle Scholar
  22. Lyttle DP, Johnson LN, Margolin EA, Madsen RW. Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2016;254:757–64.CrossRefGoogle Scholar
  23. Mandai M, Watanabe A, Kurimoto Y, et al. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med 2017;376:1038–46.CrossRefGoogle Scholar
  24. Raftopoulos R, Hickman SJ, Toosy A, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:259–69.CrossRefGoogle Scholar
  25. Sättler MB, Williams SK, Neusch C, et al. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am J Pathol 2008;173:1496–507.CrossRefGoogle Scholar
  26. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015;385:509–16.CrossRefGoogle Scholar
  27. Sears JE, Hoppe G, Ebrahem Q, et al. Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. PNAS 2008;105:19898–903.CrossRefGoogle Scholar
  28. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010;2:CD006539.Google Scholar
  29. Sene A, Khan AA, Cox D, et al. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metabolism 2013;17:549–61.CrossRefGoogle Scholar
  30. Shen J, Ghai K, Sompol P, et al. N-acetyl serotonin derivatives as potent neuroprotectants for retinas. Proc Natl Acad Sci U S A 2012;109:3540–5.CrossRefGoogle Scholar
  31. Shindler KS, Ventura E, Dutt M, et al. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 2010;30:328–39.CrossRefGoogle Scholar
  32. Shirai H, Mandai M, Matsushita K, et al. Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration. Proc Natl Acad Sci U S A 2016;113:E81–90.Sühs et al 2014CrossRefGoogle Scholar
  33. Sur A, Kesaraju S, Prentice H, et al. Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α. Proc Natl Acad Sci U S A 2014;111:16754–9.CrossRefGoogle Scholar
  34. Wiley LA, Burnight ER, Songstad AE, et al. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases. Prog Retin Eye Res 2015;44:15–35.CrossRefGoogle Scholar
  35. Wykoff CC, Clark WL, Nielsen JS, et al. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. J Manag Care Spec Pharm 2018;24(2-a Suppl):S3-S15.PubMedGoogle Scholar
  36. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. PNAS 2011;108:6241–5.CrossRefGoogle Scholar
  37. Zheng A, Li Y, Tsang SH. Personalized therapeutic strategies for patients with retinitis pigmentosa. Expert Opin Biol Ther 2015;15:391–402.CrossRefGoogle Scholar
  38. Zuo L, Khan RS, Lee V, et al. SIRT1 promotes RGC survival and delays loss of function following optic nerve crush. Invest Ophthalmol Vis Sci 2013;54:5097–102.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kewal K. Jain
    • 1
  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations